116 related articles for article (PubMed ID: 7393091)
1. Profile of a new vasodilator antihypertensive agent endralazine (BQ 22708).
Oates HF
Med J Aust; 1980 Apr; 1(8):393. PubMed ID: 7393091
[No Abstract] [Full Text] [Related]
2. Effects of the vasodilator endralazine given with the antihypertensive agent guanfacine on heart rate and blood pressure of spontaneously hypertensive rats and normotensive dogs.
Salzmann R; Gerber W; Pally C; Scholtysik G
J Pharm Pharmacol; 1983 May; 35(5):293-8. PubMed ID: 6134797
[TBL] [Abstract][Full Text] [Related]
3. Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine.
Oates HF; Stoker LM
Clin Exp Pharmacol Physiol; 1981; 8(2):133-9. PubMed ID: 7018762
[TBL] [Abstract][Full Text] [Related]
4. Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine.
Kindler J; Rüegg PC; Neuray M; Pacha W
Eur J Clin Pharmacol; 1987; 32(4):367-72. PubMed ID: 3609114
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of the acute antihypertensive and vasodilator actions of several beta-adrenoceptor antagonists.
Sybertz EJ; Baum T; Pula KK; Nelson S; Eynon E; Sabin C
J Cardiovasc Pharmacol; 1982; 4(5):749-58. PubMed ID: 6182405
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive and vasodilator effect of A-80b, a new pyridazino indole derivative.
Frechilla D; Bernedo E; Castiella E; Lasheras B; Cenarruzabeitia E; Monge A; Aldana I; Alvarez T; Losa MJ; Font M
Eur J Pharmacol; 1992 Sep; 219(3):409-14. PubMed ID: 1425969
[TBL] [Abstract][Full Text] [Related]
7. Studies on agents with vasodilator and beta-blocking activities. IV.
Seki T; Nakao T; Masuda T; Hasumi K; Gotanda K; Ishimori T; Honma S; Minami N; Shibata K; Yasuda K
Chem Pharm Bull (Tokyo); 1996 Nov; 44(11):2061-9. PubMed ID: 8945771
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives.
Elliott HL; Meredith PA; Howden CW; Lawrie CB; Reid JL
Int J Clin Pharmacol Res; 1984; 4(1):61-9. PubMed ID: 6469433
[TBL] [Abstract][Full Text] [Related]
9. Studies on agents with vasodilator and beta-blocking activities. I.
Seki T; Takezaki T; Ohuchi R; Ohuyabu H; Ishimori T; Yasuda K
Chem Pharm Bull (Tokyo); 1994 Aug; 42(8):1609-16. PubMed ID: 7954913
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine.
Elliott HL; Meredith PA; Reid JL
J Hypertens Suppl; 1984 Dec; 2(3):S551-4. PubMed ID: 6599716
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacologic effects of the antihypertensive 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido[4,3-c]pyridazine (BQ 22-708, endralazine)].
Salzmann R; Bürki H; Chu D; Clark B; Marbach P; Markstein R; Reinert H; Siegl H; Waite R
Arzneimittelforschung; 1979; 29(12):1843-53. PubMed ID: 232662
[No Abstract] [Full Text] [Related]
12. Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug.
Semeraro C; Dorigotti L; Banfi S; Carpi C
J Cardiovasc Pharmacol; 1981; 3(3):455-67. PubMed ID: 6168827
[TBL] [Abstract][Full Text] [Related]
13. Effect of 3-hydrazino-6[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) on renin in hypertensive rats.
Kawashima K; Watanabe TX; Sokabe H
Jpn J Pharmacol; 1980 Feb; 30(1):116-8. PubMed ID: 6995653
[No Abstract] [Full Text] [Related]
14. Hemodynamic profile of a new antihypertensive agent D,L-3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine (SK&F 92657).
Taylor EM; Cameron D; Eden RJ; Fielden R; Owen DA
J Cardiovasc Pharmacol; 1981; 3(2):337-54. PubMed ID: 6166805
[TBL] [Abstract][Full Text] [Related]
15. Studies on agents with vasodilator and beta-blocking activities. III. Synthesis and activity of optical isomers of TZC-1370.
Seki T; Takezaki T; Ohuchi R; Saitoh M; Ishimori T; Yasuda K
Chem Pharm Bull (Tokyo); 1995 Oct; 43(10):1719-23. PubMed ID: 8536346
[TBL] [Abstract][Full Text] [Related]
16. Studies on agents with vasodilator and beta-blocking activities. II.
Seki T; Takezaki T; Ohuchi R; Ohuyabu H; Tanimoto Y; Yamaguchi T; Saitoh M; Ishimori T; Yasuda K
Chem Pharm Bull (Tokyo); 1995 Feb; 43(2):247-55. PubMed ID: 7728931
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and pharmacokinetic studies on prizidilol and nipradilol (K-351), antihypertensive drugs with combined vasodilator and beta-adrenoceptor blocking actions, in rabbits.
Kawashima K; Watanabe TX; Sokabe H
Jpn J Pharmacol; 1984 Dec; 36(4):519-26. PubMed ID: 6151998
[TBL] [Abstract][Full Text] [Related]
18. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
Holmes DG; Bogers WA; Wideroe TE; Huunan-Seppala A; Wideroe B
Lancet; 1983 Mar; 1(8326 Pt 1):670-1. PubMed ID: 6132036
[TBL] [Abstract][Full Text] [Related]
19. Acute haemodynamic effects of endralazine in patients with coronary artery disease and stable angina pectoris.
van der Wall EE; de Feyter PJ; Res JC; Roos JP; van Engelen CL
Postgrad Med J; 1983; 59 Suppl 3():42-4. PubMed ID: 6647210
[TBL] [Abstract][Full Text] [Related]
20. Influence of preexperimental blood pressure level on hypotensive responses to vasodilator drugs.
Serrano JS; Pelayo F; Tamargo JL; García De Jalón PD
Arch Farmacol Toxicol; 1975 Aug; 1(2):91-8. PubMed ID: 1230033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
